Ser293
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.1.1
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser293  -  SLC39A7 (human)

Site Information
VQKRRGGstVPkDGP   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 18015864

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 3 ) , mutation of modification site ( 1 )
Disease tissue studied:
breast cancer ( 1 ) , cervical cancer ( 3 ) , cervical adenocarcinoma ( 3 )
Relevant cell line - cell type - tissue:
HeLa S3 (cervical) ( 3 ) , MCF-7 (breast cell) ( 1 )

Upstream Regulation
Treatments:
nocodazole ( 3 )

Downstream Regulation
Effects of modification on SLC39A7:
activity, induced ( 1 ) , phosphorylation ( 1 )
Effects of modification on biological processes:
exocytosis, induced ( 1 ) , signaling pathway regulation ( 1 )

References 

1

Nimmanon T, et al. (2017) Phosphorylation of zinc channel ZIP7 drives MAPK, PI3K and mTOR growth and proliferation signalling. Metallomics 9, 471-481
28205653   Curated Info

2

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

3

Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3
20068231   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2019 Cell Signaling Technology, Inc.